DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/f5glpx/cushings_syndrome) has announced the addition of GlobalData's new report "Cushing's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Cushing's Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Cushing's Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Cushing's Syndrome Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the global Cushing's Syndrome Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Cushing's Syndrome Therapeutics Market Forecast to Display High Growth until 2019
GlobalData estimates that the global Cushing's syndrome therapeutics market (France, Germany, Italy, Japan, Spain, The UK and The US) was worth $45.2m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 6.2% during 2006-2011. The market is expected to witness a CAGR of 9.1% from 2011-2019, to be worth $90.8m by 2019. The current treatment options available for Cushing's syndrome consist of surgery, radiation therapy and drug therapy, or a combination of these. There is no Food and Drug Administration (FDA) approved drug available in the Cushing's syndrome therapeutics market and market is completely dominated by off-label drugs (drugs that are not approved by any regulatory agency for the indication).
Drug therapy is not considered the first line of treatment option for Cushing's syndrome. The drug therapy is considered a second or third-line treatment option. The drug therapies are primarily prescribed in relapse cases of Cushing's syndrome or those patients who are not suitable for the surgery. Sometimes, drug therapy and radiation therapy combined together for the effective management of Cushing's syndrome.
Companies Mentioned
- Novartis AG (Novartis)
- Corcept Therapeutics Incorporated
- HRA Pharma, SA
- Ipsen S.A
- Samaritan Pharmaceuticals, Inc.
For more information visit http://www.researchandmarkets.com/research/f5glpx/cushings_syndrome
Source: GlobalData